Alzamend Neuro, Inc. (NASDAQ:ALZN) Short Interest Down 47.0% in March

Alzamend Neuro, Inc. (NASDAQ:ALZN) was the recipient of a large decline in short interest during the month of March. As of March 15th, there was short interest totalling 120,900 shares, a decline of 47.0% from the February 28th total of 228,200 shares. Based on an average daily trading volume, of 376,700 shares, the short-interest ratio is presently 0.3 days. Approximately 1.9% of the company’s stock are sold short.

Wall Street Analyst Weigh In

Separately, Ascendiant Capital Markets decreased their price objective on Alzamend Neuro from $32.00 to $20.00 and set a “buy” rating for the company in a report on Monday, March 17th.

Institutional Investors Weigh In On Alzamend Neuro

An institutional investor recently bought a new position in Alzamend Neuro stock. Citadel Advisors LLC acquired a new stake in Alzamend Neuro, Inc. (NASDAQ:ALZN) during the 4th quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor acquired 30,638 shares of the company’s stock, valued at approximately $36,000. Citadel Advisors LLC owned 0.56% of Alzamend Neuro as of its most recent SEC filing. 49.61% of the stock is currently owned by institutional investors and hedge funds.

Alzamend Neuro Trading Down 3.6 %

Shares of Alzamend Neuro stock opened at $1.06 on Friday. Alzamend Neuro has a 12-month low of $0.64 and a 12-month high of $15.06. The business’s 50 day moving average is $0.99 and its 200-day moving average is $1.29.

Alzamend Neuro (NASDAQ:ALZN) last issued its earnings results on Monday, March 10th. The company reported ($0.19) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.29) by $0.10. On average, equities research analysts expect that Alzamend Neuro will post -1.68 EPS for the current year.

About Alzamend Neuro

Alzamend Neuro, Inc, an early clinical-stage biopharmaceutical company, focuses on developing various products for the treatment of neurodegenerative and psychiatric disorders. The company's pipeline includes AL001, which delivers a therapeutic combination of lithium, proline, and salicylate for the treatment of Alzheimer's, bi-polar disorder, post-traumatic stress disorder, major depressive disorder, other neurodegenerative diseases, and psychiatric disorders; and ALZN002 stage, which uses a method using a mutant-peptide sensitized cell as a cell-based therapeutic vaccine to restore the ability of a patient's immunological system to combat Alzheimer's disease.